Company Details
LY
Lynparza
One MedImmune Way, Gaithersburg, MD, 20878, United States
Overview
Lynparza is a PARP inhibitor developed by AstraZeneca. The article notes it was the first PARP inhibitor from AstraZeneca to win US approval in 2014. It has secured its third EU approval. The piece does not provide product details, indication specifics, or operating metrics. Additional details in the full article require signing up for access.
- Total raised
- $16M
- Funding rounds
- 1
- Latest round
- Equity
- Latest activity
- Apr 2019
Industries
- Health Care
- Pharmaceutical
Recent funding
Equity
Apr 2019
$16M
Team
No current team members are available.